Abstract
Quinone oxidoreductase 2 (NQO2) binds the prodrug tretazicar (also known as CB1954, 5-(aziridin-1-yl)-2,4-dinitrobenzamide), which exhibits a profound antitumor effect in human cancers when administered together with caricotamide. X-ray structure determination allowed for two possible orientations of the ligand. Here we describe a new NMR method, SALMON (solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy), based on waterLOGSY to determine the orientation of a ligand bound to a protein by mapping its solvent accessibility, which was used to unambiguously determine the orientation of CB1954 in NQO2.
| Original language | English |
|---|---|
| Journal | Journal of Medicinal Chemistry |
| Volume | 51 |
| Issue number | 1 |
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| ISSN | 0022-2623 |
| DOIs | |
| Publication status | Published - 10.01.2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Fingerprint
Dive into the research topics of 'SALMON: Solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver